| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 46 | 2022 | 5450 | 2.990 |
Why?
|
| Adenocarcinoma | 32 | 2022 | 6360 | 2.090 |
Why?
|
| Deoxycytidine | 9 | 2008 | 886 | 1.560 |
Why?
|
| Pancreaticoduodenectomy | 4 | 2020 | 515 | 1.540 |
Why?
|
| Cell Adhesion Molecules | 10 | 2005 | 1609 | 1.340 |
Why?
|
| Patient Discharge | 5 | 2020 | 3460 | 1.290 |
Why?
|
| Antigens, Neoplasm | 10 | 2005 | 1995 | 1.190 |
Why?
|
| HMGA1a Protein | 4 | 2009 | 63 | 1.180 |
Why?
|
| General Surgery | 16 | 2024 | 1722 | 1.180 |
Why?
|
| Antimetabolites, Antineoplastic | 8 | 2008 | 645 | 1.170 |
Why?
|
| Pancreatectomy | 9 | 2022 | 824 | 1.040 |
Why?
|
| RNA Interference | 14 | 2010 | 2829 | 1.030 |
Why?
|
| Perioperative Care | 6 | 2019 | 1042 | 1.000 |
Why?
|
| Skilled Nursing Facilities | 2 | 2019 | 407 | 0.950 |
Why?
|
| Hepatectomy | 2 | 2019 | 588 | 0.940 |
Why?
|
| Monosaccharide Transport Proteins | 8 | 2005 | 437 | 0.920 |
Why?
|
| Matrix Metalloproteinase 2 | 5 | 2004 | 462 | 0.840 |
Why?
|
| Tissue Engineering | 8 | 2008 | 1857 | 0.820 |
Why?
|
| src-Family Kinases | 8 | 2012 | 538 | 0.800 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 4 | 2006 | 31 | 0.800 |
Why?
|
| Protein-Tyrosine Kinases | 10 | 2012 | 2423 | 0.780 |
Why?
|
| Digestive System Surgical Procedures | 4 | 2019 | 581 | 0.780 |
Why?
|
| Patient Transfer | 2 | 2019 | 789 | 0.760 |
Why?
|
| Reoperation | 6 | 2021 | 4308 | 0.750 |
Why?
|
| Anoikis | 3 | 2007 | 49 | 0.730 |
Why?
|
| Intestine, Small | 11 | 2005 | 1216 | 0.720 |
Why?
|
| Colectomy | 3 | 2020 | 697 | 0.710 |
Why?
|
| Jejunum | 11 | 2005 | 474 | 0.710 |
Why?
|
| Postoperative Complications | 18 | 2021 | 15802 | 0.700 |
Why?
|
| Cholecystectomy | 3 | 2008 | 409 | 0.700 |
Why?
|
| Internship and Residency | 18 | 2024 | 5945 | 0.660 |
Why?
|
| Neoplasm Invasiveness | 13 | 2012 | 3599 | 0.590 |
Why?
|
| Length of Stay | 8 | 2020 | 6486 | 0.590 |
Why?
|
| Intestines | 7 | 2008 | 1906 | 0.590 |
Why?
|
| Pancreatitis | 4 | 2008 | 1086 | 0.560 |
Why?
|
| Rehabilitation Centers | 1 | 2019 | 244 | 0.560 |
Why?
|
| HMGA Proteins | 2 | 2007 | 7 | 0.560 |
Why?
|
| RNA, Small Interfering | 10 | 2009 | 3419 | 0.560 |
Why?
|
| Cathartics | 1 | 2018 | 129 | 0.550 |
Why?
|
| Cell Division | 16 | 2006 | 4466 | 0.540 |
Why?
|
| Hospices | 1 | 2019 | 245 | 0.540 |
Why?
|
| Specialties, Surgical | 2 | 2020 | 390 | 0.540 |
Why?
|
| Peptides | 12 | 2005 | 4331 | 0.530 |
Why?
|
| Intestinal Mucosa | 11 | 2005 | 3048 | 0.520 |
Why?
|
| Colon | 7 | 2019 | 1796 | 0.510 |
Why?
|
| GPI-Linked Proteins | 10 | 2005 | 472 | 0.500 |
Why?
|
| Cell Line, Tumor | 31 | 2012 | 17060 | 0.470 |
Why?
|
| Receptor, EphA2 | 2 | 2004 | 41 | 0.460 |
Why?
|
| Rectum | 5 | 2019 | 895 | 0.450 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2015 | 1759 | 0.440 |
Why?
|
| Organizational Innovation | 1 | 2017 | 540 | 0.430 |
Why?
|
| Mice, Nude | 11 | 2008 | 3608 | 0.420 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 641 | 0.410 |
Why?
|
| Gallbladder Neoplasms | 2 | 2005 | 190 | 0.410 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 744 | 0.370 |
Why?
|
| Caspases | 8 | 2006 | 880 | 0.370 |
Why?
|
| Gene Silencing | 4 | 2004 | 1504 | 0.360 |
Why?
|
| Retirement | 3 | 2021 | 198 | 0.350 |
Why?
|
| Tumor Cells, Cultured | 11 | 2012 | 6101 | 0.350 |
Why?
|
| Humans | 136 | 2024 | 765926 | 0.330 |
Why?
|
| Oncogene Protein v-akt | 2 | 2007 | 130 | 0.330 |
Why?
|
| Financial Management | 2 | 2022 | 161 | 0.330 |
Why?
|
| Short Bowel Syndrome | 3 | 2002 | 352 | 0.330 |
Why?
|
| Thyroid Neoplasms | 10 | 2012 | 2354 | 0.320 |
Why?
|
| Rats, Inbred Lew | 8 | 2008 | 1167 | 0.320 |
Why?
|
| Adaptation, Physiological | 8 | 2005 | 1308 | 0.320 |
Why?
|
| Stomach Neoplasms | 2 | 2013 | 1469 | 0.310 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2006 | 636 | 0.310 |
Why?
|
| Neovascularization, Physiologic | 2 | 2008 | 1370 | 0.310 |
Why?
|
| Intestinal Diseases | 2 | 2004 | 506 | 0.310 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2009 | 5333 | 0.300 |
Why?
|
| Membrane Glycoproteins | 6 | 2004 | 3690 | 0.290 |
Why?
|
| Ileus | 2 | 2016 | 65 | 0.290 |
Why?
|
| Choledocholithiasis | 1 | 2008 | 50 | 0.290 |
Why?
|
| Neoplasm Staging | 7 | 2016 | 11196 | 0.290 |
Why?
|
| Clinical Competence | 7 | 2024 | 4855 | 0.280 |
Why?
|
| Enteritis | 2 | 2000 | 162 | 0.280 |
Why?
|
| Carcinoid Tumor | 2 | 2011 | 225 | 0.280 |
Why?
|
| Aged | 43 | 2021 | 171163 | 0.280 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2007 | 112 | 0.280 |
Why?
|
| Male | 71 | 2024 | 363815 | 0.280 |
Why?
|
| Focal Adhesion Kinase 1 | 5 | 2004 | 120 | 0.280 |
Why?
|
| Intestinal Absorption | 7 | 2000 | 400 | 0.280 |
Why?
|
| Education, Medical, Graduate | 8 | 2024 | 2419 | 0.270 |
Why?
|
| Vascular Neoplasms | 1 | 2008 | 167 | 0.270 |
Why?
|
| Apoptosis | 15 | 2011 | 9505 | 0.270 |
Why?
|
| Time Factors | 18 | 2020 | 40097 | 0.270 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 5 | 2004 | 182 | 0.270 |
Why?
|
| Bile Ducts | 1 | 2008 | 288 | 0.270 |
Why?
|
| Antigens, CD | 10 | 2005 | 4023 | 0.270 |
Why?
|
| Carcinoma, Papillary | 6 | 2011 | 786 | 0.270 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 318 | 0.270 |
Why?
|
| Chewing Gum | 1 | 2006 | 40 | 0.260 |
Why?
|
| Transplantation, Isogeneic | 2 | 2004 | 250 | 0.260 |
Why?
|
| Glucagon-Like Peptide 2 | 8 | 2005 | 45 | 0.260 |
Why?
|
| Neoplasm Transplantation | 6 | 2004 | 2008 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2009 | 2455 | 0.250 |
Why?
|
| Gallstones | 1 | 2008 | 285 | 0.250 |
Why?
|
| RNA Transport | 1 | 2005 | 42 | 0.250 |
Why?
|
| NF-kappa B | 4 | 2011 | 2492 | 0.250 |
Why?
|
| Cystadenocarcinoma | 1 | 2005 | 54 | 0.240 |
Why?
|
| Patient Readmission | 5 | 2020 | 3282 | 0.240 |
Why?
|
| Middle Aged | 41 | 2021 | 223016 | 0.240 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2005 | 82 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2008 | 3498 | 0.240 |
Why?
|
| Cystadenoma | 1 | 2005 | 76 | 0.240 |
Why?
|
| Dinoprostone | 2 | 2004 | 591 | 0.240 |
Why?
|
| Cardia | 1 | 2004 | 61 | 0.240 |
Why?
|
| Laparoscopy | 4 | 2021 | 2037 | 0.240 |
Why?
|
| Caspase 3 | 5 | 2009 | 731 | 0.230 |
Why?
|
| Rats | 23 | 2010 | 23708 | 0.230 |
Why?
|
| Female | 66 | 2024 | 396141 | 0.230 |
Why?
|
| Enzyme Activation | 6 | 2012 | 3583 | 0.230 |
Why?
|
| Veins | 1 | 2008 | 768 | 0.230 |
Why?
|
| Hernia | 1 | 2004 | 67 | 0.230 |
Why?
|
| Blotting, Western | 7 | 2010 | 5019 | 0.230 |
Why?
|
| Glucagon-Like Peptides | 8 | 2005 | 157 | 0.220 |
Why?
|
| Myosin Type II | 1 | 2004 | 71 | 0.220 |
Why?
|
| Fetal Death | 2 | 2011 | 434 | 0.220 |
Why?
|
| Caveolins | 1 | 2004 | 102 | 0.220 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2004 | 102 | 0.220 |
Why?
|
| Fibronectins | 2 | 2004 | 720 | 0.220 |
Why?
|
| Brachial Plexus | 1 | 2005 | 171 | 0.220 |
Why?
|
| Pancreatitis, Acute Necrotizing | 4 | 2009 | 174 | 0.220 |
Why?
|
| Neuroendocrine Tumors | 1 | 2010 | 655 | 0.210 |
Why?
|
| Quality Improvement | 4 | 2020 | 3847 | 0.210 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 2005 | 497 | 0.210 |
Why?
|
| Decision Support Techniques | 2 | 2015 | 2004 | 0.210 |
Why?
|
| Survival Rate | 12 | 2021 | 12822 | 0.210 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2003 | 147 | 0.210 |
Why?
|
| Isoenzymes | 3 | 2004 | 1688 | 0.210 |
Why?
|
| Enterocytes | 3 | 2003 | 220 | 0.210 |
Why?
|
| Lymphangiogenesis | 1 | 2004 | 171 | 0.210 |
Why?
|
| Transfection | 6 | 2006 | 5738 | 0.200 |
Why?
|
| Duodenal Neoplasms | 1 | 2003 | 114 | 0.200 |
Why?
|
| Peptide Hormones | 1 | 2003 | 133 | 0.200 |
Why?
|
| Colorectal Neoplasms | 2 | 2019 | 6958 | 0.200 |
Why?
|
| Aged, 80 and over | 22 | 2019 | 59496 | 0.200 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2005 | 4520 | 0.190 |
Why?
|
| Adenocarcinoma, Papillary | 3 | 2012 | 86 | 0.190 |
Why?
|
| Appendiceal Neoplasms | 1 | 2004 | 155 | 0.190 |
Why?
|
| Gastrointestinal Hormones | 2 | 2004 | 101 | 0.190 |
Why?
|
| Phosphorylation | 10 | 2012 | 8279 | 0.190 |
Why?
|
| Boston | 8 | 2024 | 9334 | 0.190 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2003 | 590 | 0.190 |
Why?
|
| Rhabdomyosarcoma | 1 | 2004 | 354 | 0.180 |
Why?
|
| Colon, Transverse | 1 | 2021 | 25 | 0.180 |
Why?
|
| Posture | 1 | 2005 | 955 | 0.180 |
Why?
|
| Gene Targeting | 1 | 2004 | 840 | 0.180 |
Why?
|
| Animals | 45 | 2011 | 168735 | 0.180 |
Why?
|
| Databases, Factual | 5 | 2020 | 8060 | 0.180 |
Why?
|
| Intestinal Neoplasms | 1 | 2003 | 314 | 0.180 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 462 | 0.180 |
Why?
|
| Retrospective Studies | 26 | 2021 | 81537 | 0.180 |
Why?
|
| Adrenal Cortex Neoplasms | 2 | 2012 | 161 | 0.180 |
Why?
|
| Membrane Proteins | 4 | 2005 | 7847 | 0.170 |
Why?
|
| Ostomy | 1 | 2020 | 34 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 7423 | 0.170 |
Why?
|
| Clinical Protocols | 4 | 2019 | 1435 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 7473 | 0.170 |
Why?
|
| Membrane Transport Proteins | 1 | 2005 | 1028 | 0.160 |
Why?
|
| Carcinoma in Situ | 1 | 2005 | 777 | 0.160 |
Why?
|
| Operating Room Technicians | 1 | 2019 | 15 | 0.160 |
Why?
|
| Bile Duct Neoplasms | 1 | 2005 | 624 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2008 | 3604 | 0.160 |
Why?
|
| Recovery of Function | 3 | 2019 | 2963 | 0.160 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2024 | 937 | 0.160 |
Why?
|
| Bilirubin | 2 | 2017 | 439 | 0.160 |
Why?
|
| Survival Analysis | 7 | 2010 | 10086 | 0.160 |
Why?
|
| Sodium-Glucose Transporter 1 | 6 | 2005 | 108 | 0.160 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 3 | 2008 | 520 | 0.160 |
Why?
|
| Autophagy | 3 | 2012 | 1350 | 0.160 |
Why?
|
| Chi-Square Distribution | 4 | 2010 | 3430 | 0.160 |
Why?
|
| Enzyme Inhibitors | 3 | 2003 | 3716 | 0.150 |
Why?
|
| Professional Practice | 1 | 2020 | 314 | 0.150 |
Why?
|
| Attitude of Health Personnel | 6 | 2021 | 3928 | 0.150 |
Why?
|
| Surgical Stapling | 1 | 2019 | 98 | 0.150 |
Why?
|
| Growth Hormone | 1 | 2001 | 567 | 0.150 |
Why?
|
| Masks | 1 | 2021 | 212 | 0.150 |
Why?
|
| Mentors | 2 | 2021 | 671 | 0.150 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2005 | 887 | 0.150 |
Why?
|
| United States | 18 | 2024 | 72909 | 0.150 |
Why?
|
| Regeneration | 2 | 2004 | 1516 | 0.150 |
Why?
|
| Prognosis | 15 | 2021 | 29890 | 0.150 |
Why?
|
| Anesthesia, General | 1 | 2005 | 1182 | 0.150 |
Why?
|
| Workload | 2 | 2005 | 848 | 0.150 |
Why?
|
| Sex Factors | 4 | 2021 | 10611 | 0.150 |
Why?
|
| Risk Assessment | 6 | 2019 | 24275 | 0.150 |
Why?
|
| Age Factors | 4 | 2020 | 18382 | 0.150 |
Why?
|
| Gene Expression Profiling | 3 | 2006 | 9525 | 0.150 |
Why?
|
| Education, Distance | 1 | 2021 | 260 | 0.140 |
Why?
|
| Palliative Care | 3 | 2021 | 3640 | 0.140 |
Why?
|
| Receptors, Gastrointestinal Hormone | 1 | 1997 | 45 | 0.140 |
Why?
|
| Galectin 3 | 2 | 2009 | 238 | 0.140 |
Why?
|
| Protozoan Proteins | 1 | 2003 | 842 | 0.140 |
Why?
|
| Ureter | 1 | 2020 | 364 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2009 | 8603 | 0.140 |
Why?
|
| North America | 2 | 2018 | 1287 | 0.140 |
Why?
|
| Analgesia, Epidural | 1 | 2020 | 332 | 0.140 |
Why?
|
| Biomedical Research | 2 | 2024 | 3458 | 0.140 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2005 | 8107 | 0.140 |
Why?
|
| Mucins | 1 | 2000 | 568 | 0.140 |
Why?
|
| Pyridines | 2 | 2012 | 2885 | 0.140 |
Why?
|
| Comorbidity | 3 | 2020 | 10575 | 0.140 |
Why?
|
| Hernia, Ventral | 1 | 2020 | 220 | 0.140 |
Why?
|
| Hospitals, Teaching | 2 | 2017 | 1156 | 0.140 |
Why?
|
| Adult | 33 | 2024 | 223088 | 0.140 |
Why?
|
| Risk Factors | 11 | 2021 | 74850 | 0.140 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2011 | 1060 | 0.140 |
Why?
|
| Teaching Rounds | 1 | 2021 | 280 | 0.140 |
Why?
|
| Menopause | 1 | 2005 | 1659 | 0.130 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 170 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2004 | 1936 | 0.130 |
Why?
|
| Neoplasm Metastasis | 2 | 2004 | 4882 | 0.130 |
Why?
|
| Pyrroles | 2 | 2012 | 1119 | 0.130 |
Why?
|
| Extracellular Matrix | 1 | 2004 | 1727 | 0.130 |
Why?
|
| Cell Culture Techniques | 1 | 2003 | 1650 | 0.130 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2000 | 521 | 0.130 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2010 | 613 | 0.130 |
Why?
|
| Robotics | 1 | 2003 | 807 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 2895 | 0.130 |
Why?
|
| Amiloride | 1 | 1996 | 116 | 0.130 |
Why?
|
| Indoles | 3 | 2012 | 1833 | 0.130 |
Why?
|
| Thyroidectomy | 1 | 2021 | 912 | 0.130 |
Why?
|
| Catheterization, Central Venous | 1 | 2021 | 538 | 0.130 |
Why?
|
| Gastric Bypass | 1 | 2004 | 820 | 0.130 |
Why?
|
| Graft Survival | 2 | 2003 | 3904 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 3733 | 0.130 |
Why?
|
| Health Status | 2 | 2019 | 4085 | 0.120 |
Why?
|
| Pregnancy Complications | 2 | 2011 | 2970 | 0.120 |
Why?
|
| Cystectomy | 1 | 2019 | 603 | 0.120 |
Why?
|
| Fluorouracil | 1 | 2000 | 1648 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2009 | 2877 | 0.120 |
Why?
|
| Sodium Channel Blockers | 1 | 1996 | 170 | 0.120 |
Why?
|
| Cell Proliferation | 6 | 2012 | 10426 | 0.120 |
Why?
|
| RNA, Messenger | 10 | 2005 | 12768 | 0.120 |
Why?
|
| Phosphoproteins | 1 | 2003 | 2444 | 0.120 |
Why?
|
| Autoantibodies | 1 | 2003 | 2114 | 0.120 |
Why?
|
| Physicians, Women | 1 | 2020 | 516 | 0.120 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 560 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2012 | 10727 | 0.110 |
Why?
|
| Intraoperative Care | 1 | 2018 | 768 | 0.110 |
Why?
|
| Gastrectomy | 2 | 2013 | 693 | 0.110 |
Why?
|
| Tyrosine | 2 | 2012 | 1427 | 0.110 |
Why?
|
| Endotoxins | 1 | 1996 | 516 | 0.110 |
Why?
|
| Antineoplastic Agents | 5 | 2015 | 13631 | 0.110 |
Why?
|
| Surgical Wound Infection | 3 | 2020 | 1544 | 0.110 |
Why?
|
| Colorectal Surgery | 1 | 2016 | 125 | 0.110 |
Why?
|
| Anesthesia, Conduction | 1 | 2017 | 263 | 0.110 |
Why?
|
| Blotting, Northern | 3 | 2005 | 1546 | 0.110 |
Why?
|
| Enzyme Induction | 2 | 2004 | 456 | 0.110 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 2008 | 236 | 0.110 |
Why?
|
| Mice | 13 | 2011 | 81782 | 0.110 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2005 | 461 | 0.110 |
Why?
|
| Serum Albumin | 1 | 2017 | 673 | 0.110 |
Why?
|
| Radiation Tolerance | 3 | 2010 | 475 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2010 | 9373 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 3542 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2011 | 2879 | 0.110 |
Why?
|
| Positive-Pressure Respiration | 1 | 2018 | 712 | 0.110 |
Why?
|
| Occupational Health | 1 | 2020 | 812 | 0.110 |
Why?
|
| Operating Rooms | 2 | 2019 | 785 | 0.110 |
Why?
|
| Hospital Costs | 1 | 2019 | 955 | 0.110 |
Why?
|
| Cell Survival | 5 | 2011 | 5745 | 0.110 |
Why?
|
| Intraoperative Period | 2 | 2019 | 510 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2003 | 2031 | 0.100 |
Why?
|
| Treatment Outcome | 10 | 2019 | 65194 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3109 | 0.100 |
Why?
|
| Sarcoma | 1 | 2003 | 1799 | 0.100 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3231 | 0.100 |
Why?
|
| Benzenesulfonates | 1 | 2012 | 170 | 0.100 |
Why?
|
| Lactones | 2 | 2004 | 316 | 0.100 |
Why?
|
| Boidae | 2 | 2002 | 14 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2005 | 2787 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 2 | 2004 | 594 | 0.100 |
Why?
|
| Healthcare Disparities | 3 | 2022 | 3407 | 0.100 |
Why?
|
| Obesity, Morbid | 2 | 2018 | 1293 | 0.100 |
Why?
|
| Transplantation, Heterologous | 3 | 2004 | 2390 | 0.100 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2012 | 88 | 0.100 |
Why?
|
| Veterans | 2 | 2024 | 2667 | 0.100 |
Why?
|
| Sulfones | 2 | 2004 | 447 | 0.100 |
Why?
|
| Pneumonia | 2 | 2020 | 2158 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2005 | 3816 | 0.090 |
Why?
|
| Appendicitis | 2 | 2011 | 680 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 4 | 2006 | 6058 | 0.090 |
Why?
|
| SEER Program | 2 | 2015 | 1443 | 0.090 |
Why?
|
| Incidence | 5 | 2019 | 21513 | 0.090 |
Why?
|
| Efficiency, Organizational | 1 | 2016 | 695 | 0.090 |
Why?
|
| Wound Healing | 1 | 2002 | 2794 | 0.090 |
Why?
|
| Drug Synergism | 4 | 2012 | 1751 | 0.090 |
Why?
|
| Ribosomal Proteins | 2 | 2003 | 367 | 0.090 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 489 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 589 | 0.090 |
Why?
|
| Signal Transduction | 8 | 2011 | 23597 | 0.090 |
Why?
|
| Education, Medical | 2 | 2022 | 1744 | 0.090 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2010 | 347 | 0.090 |
Why?
|
| Cross-Linking Reagents | 2 | 2004 | 687 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2016 | 1186 | 0.090 |
Why?
|
| Forecasting | 2 | 2018 | 2936 | 0.090 |
Why?
|
| Pancreas | 4 | 2022 | 1698 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 6503 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2011 | 2897 | 0.090 |
Why?
|
| Sulindac | 1 | 2010 | 29 | 0.090 |
Why?
|
| Doxorubicin | 4 | 2010 | 2226 | 0.090 |
Why?
|
| Pain, Postoperative | 2 | 2019 | 1767 | 0.090 |
Why?
|
| Thromboembolism | 1 | 2017 | 1001 | 0.090 |
Why?
|
| Analgesics | 1 | 2017 | 1057 | 0.090 |
Why?
|
| Heart Arrest | 1 | 2020 | 1516 | 0.090 |
Why?
|
| Anastomosis, Surgical | 3 | 2021 | 992 | 0.090 |
Why?
|
| Blood Transfusion | 1 | 2017 | 1307 | 0.090 |
Why?
|
| DNA Primers | 2 | 2006 | 2824 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 1666 | 0.090 |
Why?
|
| Veterans Health | 2 | 2022 | 216 | 0.090 |
Why?
|
| Glucose Transporter Type 2 | 3 | 2005 | 61 | 0.090 |
Why?
|
| Epithelial Cells | 1 | 2002 | 3684 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2017 | 2426 | 0.080 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2005 | 3682 | 0.080 |
Why?
|
| Thioglycosides | 1 | 2009 | 8 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 3 | 2006 | 5784 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2021 | 1878 | 0.080 |
Why?
|
| Morbidity | 3 | 2020 | 1752 | 0.080 |
Why?
|
| Logistic Models | 2 | 2019 | 13273 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2010 | 6202 | 0.080 |
Why?
|
| Animals, Newborn | 3 | 2003 | 2676 | 0.080 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 1183 | 0.080 |
Why?
|
| Flavonoids | 1 | 2012 | 445 | 0.080 |
Why?
|
| Epidermal Growth Factor | 1 | 2011 | 697 | 0.080 |
Why?
|
| Medicine | 2 | 2016 | 944 | 0.080 |
Why?
|
| Up-Regulation | 4 | 2012 | 4130 | 0.080 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2008 | 44 | 0.080 |
Why?
|
| Pandemics | 4 | 2021 | 8721 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2009 | 678 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2008 | 20690 | 0.070 |
Why?
|
| Bariatric Surgery | 1 | 2018 | 997 | 0.070 |
Why?
|
| Models, Biological | 1 | 2004 | 9443 | 0.070 |
Why?
|
| Cell Movement | 3 | 2004 | 5190 | 0.070 |
Why?
|
| Circadian Rhythm | 3 | 2005 | 2594 | 0.070 |
Why?
|
| Transcription Factors | 2 | 2004 | 12129 | 0.070 |
Why?
|
| Stents | 1 | 2020 | 3191 | 0.070 |
Why?
|
| Cholangiography | 1 | 2008 | 182 | 0.070 |
Why?
|
| Thyroid Gland | 2 | 2011 | 1168 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 1804 | 0.070 |
Why?
|
| Acute Disease | 3 | 2008 | 7236 | 0.070 |
Why?
|
| Appendectomy | 1 | 2011 | 445 | 0.070 |
Why?
|
| Sepsis | 2 | 2019 | 2603 | 0.070 |
Why?
|
| Sucrase | 2 | 2005 | 51 | 0.070 |
Why?
|
| Cell Adhesion | 2 | 2004 | 3089 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2019 | 2176 | 0.070 |
Why?
|
| Cells, Cultured | 4 | 2010 | 18962 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2006 | 3796 | 0.070 |
Why?
|
| Sirolimus | 2 | 2012 | 1541 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2013 | 1888 | 0.070 |
Why?
|
| Receptors, Glucagon | 2 | 2004 | 90 | 0.070 |
Why?
|
| New Zealand | 2 | 2017 | 359 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 5509 | 0.070 |
Why?
|
| Liver Function Tests | 1 | 2008 | 527 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2010 | 561 | 0.070 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 2782 | 0.070 |
Why?
|
| Cell Death | 1 | 2011 | 1676 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2007 | 380 | 0.070 |
Why?
|
| Sodium | 5 | 2002 | 1591 | 0.060 |
Why?
|
| Pancreatic Diseases | 1 | 2008 | 353 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2017 | 2515 | 0.060 |
Why?
|
| Carbapenems | 1 | 2007 | 125 | 0.060 |
Why?
|
| Mortality | 1 | 2017 | 2910 | 0.060 |
Why?
|
| Base Sequence | 4 | 2006 | 12405 | 0.060 |
Why?
|
| Ion Transport | 2 | 1997 | 322 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 1930 | 0.060 |
Why?
|
| Glycogen Synthase Kinases | 1 | 2005 | 40 | 0.060 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 1258 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2008 | 634 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2011 | 889 | 0.060 |
Why?
|
| beta Catenin | 1 | 2010 | 1046 | 0.060 |
Why?
|
| Genes, src | 1 | 2004 | 51 | 0.060 |
Why?
|
| Ephrin-A1 | 1 | 2004 | 9 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2002 | 10256 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1695 | 0.060 |
Why?
|
| Cell Count | 2 | 2010 | 1823 | 0.060 |
Why?
|
| Vitronectin | 1 | 2004 | 40 | 0.060 |
Why?
|
| Probability | 1 | 2010 | 2474 | 0.060 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2004 | 65 | 0.060 |
Why?
|
| Phlorhizin | 2 | 2001 | 37 | 0.060 |
Why?
|
| Pyrimidines | 3 | 2012 | 3049 | 0.060 |
Why?
|
| Keratins | 1 | 2006 | 497 | 0.060 |
Why?
|
| Receptor, EphB3 | 1 | 2003 | 11 | 0.060 |
Why?
|
| Molecular Structure | 2 | 2009 | 1880 | 0.060 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2004 | 186 | 0.060 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 2004 | 74 | 0.060 |
Why?
|
| Neural Conduction | 1 | 2005 | 442 | 0.060 |
Why?
|
| RNA-Induced Silencing Complex | 1 | 2004 | 52 | 0.060 |
Why?
|
| Paralysis | 1 | 2005 | 248 | 0.060 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 39228 | 0.060 |
Why?
|
| Vinculin | 1 | 2003 | 58 | 0.060 |
Why?
|
| Quinones | 1 | 2003 | 78 | 0.060 |
Why?
|
| Rifabutin | 1 | 2003 | 52 | 0.060 |
Why?
|
| E2F1 Transcription Factor | 1 | 2004 | 183 | 0.060 |
Why?
|
| Genistein | 1 | 2003 | 87 | 0.050 |
Why?
|
| Mycoses | 1 | 2007 | 389 | 0.050 |
Why?
|
| World Health Organization | 1 | 2010 | 1326 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2004 | 118 | 0.050 |
Why?
|
| Cytochromes c | 1 | 2004 | 173 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2016 | 2520 | 0.050 |
Why?
|
| Lentivirus | 1 | 2006 | 518 | 0.050 |
Why?
|
| Catheterization | 1 | 2009 | 1426 | 0.050 |
Why?
|
| Intestine, Large | 1 | 2003 | 69 | 0.050 |
Why?
|
| E2F Transcription Factors | 1 | 2004 | 269 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2004 | 313 | 0.050 |
Why?
|
| Brunner Glands | 1 | 2003 | 11 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 3834 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2008 | 1777 | 0.050 |
Why?
|
| Benzoquinones | 1 | 2003 | 197 | 0.050 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2004 | 280 | 0.050 |
Why?
|
| Faculty, Medical | 2 | 2023 | 1225 | 0.050 |
Why?
|
| Work Schedule Tolerance | 2 | 2005 | 553 | 0.050 |
Why?
|
| Infarction | 1 | 2004 | 247 | 0.050 |
Why?
|
| Intestinal Polyps | 1 | 2003 | 105 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2008 | 11030 | 0.050 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 2002 | 54 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2006 | 1524 | 0.050 |
Why?
|
| Hydrochloric Acid | 1 | 2002 | 76 | 0.050 |
Why?
|
| Laminin | 1 | 2004 | 404 | 0.050 |
Why?
|
| Vagus Nerve | 1 | 2005 | 458 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 411 | 0.050 |
Why?
|
| Ileum | 1 | 2005 | 558 | 0.050 |
Why?
|
| Luciferases | 1 | 2004 | 712 | 0.050 |
Why?
|
| Educational Measurement | 2 | 2020 | 1260 | 0.050 |
Why?
|
| Caveolin 1 | 1 | 2004 | 255 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2004 | 628 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 361 | 0.050 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2004 | 287 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 610 | 0.050 |
Why?
|
| Socioeconomic Factors | 3 | 2022 | 7842 | 0.050 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2004 | 318 | 0.050 |
Why?
|
| Thymidine | 1 | 2002 | 294 | 0.050 |
Why?
|
| Myosin Light Chains | 1 | 2002 | 122 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2003 | 1140 | 0.050 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2004 | 385 | 0.050 |
Why?
|
| Lactams, Macrocyclic | 1 | 2003 | 318 | 0.050 |
Why?
|
| Professional Autonomy | 1 | 2023 | 172 | 0.050 |
Why?
|
| Cachexia | 1 | 2003 | 200 | 0.050 |
Why?
|
| Retroviridae | 1 | 2004 | 845 | 0.050 |
Why?
|
| Tritium | 1 | 2002 | 702 | 0.050 |
Why?
|
| Androstadienes | 1 | 2003 | 347 | 0.050 |
Why?
|
| Placebos | 1 | 2006 | 1659 | 0.050 |
Why?
|
| Ghrelin | 1 | 2003 | 255 | 0.050 |
Why?
|
| Dogs | 5 | 2000 | 3824 | 0.050 |
Why?
|
| Gene Expression Regulation | 3 | 2005 | 11895 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2005 | 12059 | 0.050 |
Why?
|
| Job Satisfaction | 1 | 2005 | 548 | 0.050 |
Why?
|
| Gene Expression | 2 | 2004 | 7581 | 0.050 |
Why?
|
| Cold Temperature | 1 | 2005 | 793 | 0.050 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2003 | 219 | 0.050 |
Why?
|
| Transplants | 1 | 2003 | 208 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2004 | 855 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2003 | 1061 | 0.050 |
Why?
|
| Cholelithiasis | 1 | 2003 | 408 | 0.050 |
Why?
|
| 3-O-Methylglucose | 1 | 2001 | 37 | 0.050 |
Why?
|
| Serine | 1 | 2005 | 825 | 0.050 |
Why?
|
| Medical Staff, Hospital | 1 | 2005 | 601 | 0.050 |
Why?
|
| History, 17th Century | 1 | 2021 | 108 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 8522 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 3801 | 0.040 |
Why?
|
| Esophagectomy | 1 | 2004 | 478 | 0.040 |
Why?
|
| History, 18th Century | 1 | 2021 | 206 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2015 | 5088 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 2795 | 0.040 |
Why?
|
| New York | 1 | 2003 | 880 | 0.040 |
Why?
|
| Personnel Turnover | 1 | 2020 | 89 | 0.040 |
Why?
|
| Amylases | 1 | 2000 | 171 | 0.040 |
Why?
|
| Research Design | 2 | 2008 | 6204 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2011 | 3447 | 0.040 |
Why?
|
| Accreditation | 1 | 2003 | 476 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 11858 | 0.040 |
Why?
|
| Cell Nucleus | 2 | 2010 | 2864 | 0.040 |
Why?
|
| Chlorides | 3 | 2002 | 666 | 0.040 |
Why?
|
| Bromodeoxyuridine | 1 | 2000 | 310 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 2530 | 0.040 |
Why?
|
| Phenols | 1 | 2003 | 526 | 0.040 |
Why?
|
| Mammals | 1 | 2005 | 1126 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2004 | 1835 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 6838 | 0.040 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2005 | 616 | 0.040 |
Why?
|
| Electrophysiology | 1 | 2002 | 1264 | 0.040 |
Why?
|
| Protein Transport | 1 | 2005 | 1938 | 0.040 |
Why?
|
| Peptide YY | 2 | 1997 | 135 | 0.040 |
Why?
|
| Genes, ras | 1 | 2002 | 656 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 11508 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 5691 | 0.040 |
Why?
|
| Cell Line | 2 | 2004 | 15540 | 0.040 |
Why?
|
| Biological Transport | 2 | 2001 | 2081 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2000 | 336 | 0.040 |
Why?
|
| Young Adult | 5 | 2013 | 59857 | 0.040 |
Why?
|
| Practice Management, Medical | 1 | 2020 | 191 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2004 | 867 | 0.040 |
Why?
|
| Endosonography | 1 | 2003 | 626 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 1885 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 2001 | 0.040 |
Why?
|
| Food | 3 | 2002 | 764 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2005 | 4349 | 0.040 |
Why?
|
| History, 19th Century | 1 | 2021 | 711 | 0.040 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2019 | 110 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2004 | 1743 | 0.040 |
Why?
|
| Specialty Boards | 1 | 2020 | 235 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 12529 | 0.040 |
Why?
|
| Stroke | 1 | 2020 | 9739 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2009 | 5880 | 0.040 |
Why?
|
| Benzamides | 1 | 2003 | 1376 | 0.040 |
Why?
|
| Electric Impedance | 1 | 2002 | 792 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 1607 | 0.040 |
Why?
|
| Career Mobility | 1 | 2020 | 261 | 0.040 |
Why?
|
| Efficiency | 1 | 2021 | 479 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2004 | 1489 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2004 | 1069 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2001 | 573 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2000 | 855 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2006 | 3400 | 0.030 |
Why?
|
| Shock | 1 | 2019 | 316 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2020 | 513 | 0.030 |
Why?
|
| Antibodies | 1 | 2005 | 2415 | 0.030 |
Why?
|
| Age of Onset | 1 | 2004 | 3343 | 0.030 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 1997 | 179 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2008 | 1926 | 0.030 |
Why?
|
| Career Choice | 2 | 2020 | 769 | 0.030 |
Why?
|
| Actins | 1 | 2004 | 2057 | 0.030 |
Why?
|
| Guideline Adherence | 2 | 2005 | 2234 | 0.030 |
Why?
|
| Adolescent | 5 | 2013 | 88811 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2004 | 1772 | 0.030 |
Why?
|
| Models, Educational | 1 | 2019 | 375 | 0.030 |
Why?
|
| Cecum | 1 | 1996 | 231 | 0.030 |
Why?
|
| Carcinoma | 3 | 2011 | 2311 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 3079 | 0.030 |
Why?
|
| Tidal Volume | 1 | 2018 | 519 | 0.030 |
Why?
|
| Recurrence | 1 | 2008 | 8492 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2005 | 3635 | 0.030 |
Why?
|
| Ligation | 1 | 1996 | 445 | 0.030 |
Why?
|
| Glucose Transporter Type 5 | 2 | 2005 | 13 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2008 | 15878 | 0.030 |
Why?
|
| Reference Values | 1 | 2002 | 4909 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2021 | 944 | 0.030 |
Why?
|
| Massachusetts | 2 | 2020 | 8882 | 0.030 |
Why?
|
| Genotype | 1 | 2009 | 13026 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2010 | 1065 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2021 | 1572 | 0.030 |
Why?
|
| Self Concept | 1 | 2020 | 1039 | 0.030 |
Why?
|
| Neoplasms | 1 | 2003 | 22340 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 6491 | 0.030 |
Why?
|
| Models, Animal | 1 | 2001 | 2120 | 0.030 |
Why?
|
| Dehydration | 1 | 2016 | 215 | 0.030 |
Why?
|
| Permeability | 1 | 1996 | 726 | 0.030 |
Why?
|
| DNA | 3 | 2004 | 7193 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 2270 | 0.030 |
Why?
|
| Health Care Reform | 1 | 2003 | 1257 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 2627 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2005 | 18292 | 0.030 |
Why?
|
| RNA | 1 | 2003 | 2716 | 0.030 |
Why?
|
| Focus Groups | 1 | 2020 | 1458 | 0.030 |
Why?
|
| Glucose | 3 | 2002 | 4335 | 0.030 |
Why?
|
| Registries | 1 | 2010 | 8346 | 0.030 |
Why?
|
| Amino Acids | 2 | 2002 | 1709 | 0.030 |
Why?
|
| Publishing | 1 | 2021 | 836 | 0.030 |
Why?
|
| Multiple Organ Failure | 2 | 2009 | 389 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2023 | 54807 | 0.030 |
Why?
|
| Income | 1 | 2022 | 1874 | 0.030 |
Why?
|
| Family | 1 | 2024 | 3208 | 0.030 |
Why?
|
| Piperazines | 1 | 2003 | 2546 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2021 | 2760 | 0.030 |
Why?
|
| Niacin | 1 | 1994 | 116 | 0.030 |
Why?
|
| Infection Control | 1 | 2020 | 984 | 0.030 |
Why?
|
| Eating | 2 | 2001 | 1539 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 3431 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 15401 | 0.030 |
Why?
|
| Aspirin | 1 | 2004 | 3135 | 0.030 |
Why?
|
| Adenoma | 1 | 2003 | 2155 | 0.020 |
Why?
|
| Netherlands | 1 | 2017 | 2277 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2017 | 811 | 0.020 |
Why?
|
| Appointments and Schedules | 1 | 2016 | 441 | 0.020 |
Why?
|
| Caco-2 Cells | 2 | 2004 | 366 | 0.020 |
Why?
|
| Research | 1 | 2000 | 1974 | 0.020 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1994 | 479 | 0.020 |
Why?
|
| Markov Chains | 1 | 2015 | 971 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2003 | 7599 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 3592 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 16714 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 6306 | 0.020 |
Why?
|
| Microvilli | 2 | 2002 | 234 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2000 | 2248 | 0.020 |
Why?
|
| Diffusion Chambers, Culture | 1 | 2010 | 49 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2010 | 116 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2012 | 228 | 0.020 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2011 | 165 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2011 | 252 | 0.020 |
Why?
|
| Niacinamide | 1 | 2012 | 419 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2019 | 2502 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2008 | 5752 | 0.020 |
Why?
|
| Thiogalactosides | 1 | 2009 | 7 | 0.020 |
Why?
|
| Drainage | 2 | 2009 | 1181 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2011 | 869 | 0.020 |
Why?
|
| Vacuoles | 1 | 2010 | 224 | 0.020 |
Why?
|
| Body Weight | 1 | 2000 | 4627 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 536 | 0.020 |
Why?
|
| Benchmarking | 1 | 2016 | 1055 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2011 | 956 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 4641 | 0.020 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2012 | 340 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 798 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 12973 | 0.020 |
Why?
|
| Fever | 1 | 2016 | 1607 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2010 | 715 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2003 | 4305 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 195 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 428 | 0.020 |
Why?
|
| Cytosol | 1 | 2010 | 885 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2012 | 862 | 0.020 |
Why?
|
| Consensus | 1 | 2017 | 3202 | 0.020 |
Why?
|
| Pregnancy | 2 | 2011 | 30230 | 0.020 |
Why?
|
| Proteins | 1 | 2002 | 5994 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 9239 | 0.020 |
Why?
|
| Mutation | 3 | 2012 | 30192 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 9600 | 0.020 |
Why?
|
| Keratin-20 | 1 | 2006 | 31 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 938 | 0.020 |
Why?
|
| Abortion, Spontaneous | 1 | 2011 | 536 | 0.020 |
Why?
|
| Keratin-7 | 1 | 2006 | 55 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2011 | 1193 | 0.020 |
Why?
|
| Vagotomy, Truncal | 1 | 2005 | 10 | 0.020 |
Why?
|
| Imidazoles | 1 | 2011 | 1164 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2010 | 1739 | 0.020 |
Why?
|
| Curriculum | 1 | 2019 | 3784 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2012 | 1621 | 0.020 |
Why?
|
| Quality of Life | 2 | 2005 | 13463 | 0.010 |
Why?
|
| Dideoxyadenosine | 1 | 2004 | 9 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 5836 | 0.010 |
Why?
|
| Metabolome | 1 | 2012 | 1005 | 0.010 |
Why?
|
| Aging | 1 | 2003 | 8725 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 2004 | 174 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1997 | 5126 | 0.010 |
Why?
|
| Thiazoles | 1 | 2012 | 1528 | 0.010 |
Why?
|
| Adenine | 1 | 2009 | 994 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 2885 | 0.010 |
Why?
|
| Data Collection | 2 | 2005 | 3318 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4563 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2010 | 2925 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 1882 | 0.010 |
Why?
|
| Algorithms | 1 | 2003 | 14064 | 0.010 |
Why?
|
| Cholera Toxin | 1 | 2004 | 562 | 0.010 |
Why?
|
| Solutions | 1 | 2002 | 405 | 0.010 |
Why?
|
| Bile | 1 | 2002 | 300 | 0.010 |
Why?
|
| Medicare | 1 | 2019 | 6815 | 0.010 |
Why?
|
| Guanosine | 1 | 2001 | 43 | 0.010 |
Why?
|
| Physical Stimulation | 1 | 2002 | 513 | 0.010 |
Why?
|
| Water | 2 | 1999 | 1416 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2823 | 0.010 |
Why?
|
| Random Allocation | 1 | 2005 | 2394 | 0.010 |
Why?
|
| Cell Size | 1 | 2002 | 626 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2004 | 1466 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2018 | 13042 | 0.010 |
Why?
|
| Kinetics | 2 | 2001 | 6273 | 0.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2010 | 2053 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2002 | 578 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 2001 | 405 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 4213 | 0.010 |
Why?
|
| Child | 2 | 2011 | 80568 | 0.010 |
Why?
|
| Lung | 1 | 2018 | 10046 | 0.010 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2002 | 314 | 0.010 |
Why?
|
| Risk | 1 | 2011 | 9599 | 0.010 |
Why?
|
| Absorption | 1 | 1999 | 242 | 0.010 |
Why?
|
| Maltose | 1 | 1999 | 39 | 0.010 |
Why?
|
| Premature Birth | 1 | 2011 | 1830 | 0.010 |
Why?
|
| Intestinal Fistula | 1 | 2000 | 146 | 0.010 |
Why?
|
| Endoscopy, Digestive System | 1 | 2001 | 358 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2000 | 473 | 0.010 |
Why?
|
| Light | 1 | 2004 | 1364 | 0.010 |
Why?
|
| Mannitol | 1 | 1999 | 176 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2000 | 478 | 0.010 |
Why?
|
| Potassium | 1 | 2002 | 1312 | 0.010 |
Why?
|
| Radiography | 1 | 2009 | 6941 | 0.010 |
Why?
|
| Organ Size | 1 | 2002 | 2261 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1999 | 564 | 0.010 |
Why?
|
| Carbohydrates | 1 | 1999 | 387 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2011 | 14450 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2003 | 21069 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 2838 | 0.010 |
Why?
|
| Specialization | 1 | 2000 | 779 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 1239 | 0.010 |
Why?
|
| Malabsorption Syndromes | 1 | 1995 | 135 | 0.010 |
Why?
|
| Ribonucleases | 1 | 1995 | 265 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2002 | 1893 | 0.010 |
Why?
|
| Neurosecretory Systems | 1 | 1995 | 223 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 1994 | 323 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 22228 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1994 | 515 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1995 | 1305 | 0.010 |
Why?
|
| Molecular Probes | 1 | 1995 | 307 | 0.010 |
Why?
|
| Glucagon | 1 | 1995 | 533 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2015 | 41680 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 3270 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 17596 | 0.010 |
Why?
|
| Duodenum | 1 | 1994 | 496 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1994 | 1527 | 0.010 |
Why?
|
| Prevalence | 1 | 2007 | 15828 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1995 | 1818 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1994 | 1887 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 14643 | 0.000 |
Why?
|
| Diet | 1 | 2000 | 8087 | 0.000 |
Why?
|